Novartis AG
N1VS34.SA
| Exchange: | SA |
| Currency | Brazilian real |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Home Category: | BDR |
| Is Delisted: | False |
| Description: | Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. |
| Address: | Lichtstrasse 35, Basel, Switzerland, 4056 |
| Website: | https://www.novartis.com |
| Full Time Employees: | 76057 |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 1292792889344 |
| Market Capitalization Mln: | 1292792.88 |
| EBITDA: | 20893999104 |
| PE Ratio: | 19.01 |
| PEG Ratio: | 3.26 |
| Book Value: | 21.66 |
| Dividend Share: | 3.91 |
| Dividend Yield: | 0.01 |
| Earnings Share: | 3.36 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.35 |
| Operating Margin TTM: | 0.33 |
| Return On Assets TTM: | 0.09 |
| Return On Equity TTM: | 0.28 |
| Revenue TTM: | 49940000768 |
| Revenue Per Share TTM: | 24.54 |
| Quarterly Revenue Growth YOY: | 0.08 |
| Gross Profit TTM: | 36744000000 |
| Diluted Eps TTM: | 3.36 |
| Quarterly Earnings Growth YOY: | 0.84 |
Valuation
| Trailing PE: | 19.01 |
| Forward PE: | 13.38 |
| Price Sales TTM: | 25.88 |
| Price Book MRQ: | 5.02 |
| Enterprise Value: | 1399277911777 |
| Enterprise Value Revenue: | 4.77 |
| Enterprise Value Ebitda: | 12.09 |
Shares
| Shares Outstanding: | 19992700928 |
| Shares Float: | 1907923385 |
Technicals
| Beta: | 0.49 |
| 52 Week High: | 68.54 |
| 52 Week Low: | 44.59 |
| 50 Day MA: | 64.71 |
| 200 Day MA: | 56.79 |
Splits & Dividends
| Forward Annual Dividend Rate: | 1.26 |
| Forward Annual Dividend Yield: | 0.01 |
| Payout Ratio: | 0.44 |
| Ex Dividend Date: | 2024-03-07 |